Alterity Therapeutics Limited (FRA:PBN)

Alterity Therapeutics Statistics

Total Valuation

FRA:PBN has a market cap or net worth of EUR 55.16 million. The enterprise value is 32.33 million.

Market Cap	55.16M
Enterprise Value	32.33M

Important Dates

The next estimated earnings date is Wednesday, February 25, 2026.

Earnings Date	Feb 25, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	10.88B
Shares Outstanding	n/a
Shares Change (YoY)	+75.31%
Shares Change (QoQ)	+40.78%
Owned by Insiders (%)	4.73%
Owned by Institutions (%)	32.32%
Float	8.31B

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	18.17
PB Ratio	2.33
P/TBV Ratio	2.33
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-4.77
EV / Sales	10.55
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 12.98, with a Debt / Equity ratio of 0.00.

Current Ratio	12.98
Quick Ratio	12.62
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -43.23% and return on invested capital (ROIC) is -32.43%.

Return on Equity (ROE)	-43.23%
Return on Assets (ROA)	-28.09%
Return on Invested Capital (ROIC)	-32.43%
Return on Capital Employed (ROCE)	-34.50%
Revenue Per Employee	337,365
Profits Per Employee	-753,504
Employee Count	9
Asset Turnover	0.17
Inventory Turnover	n/a

Taxes

In the past 12 months, FRA:PBN has paid 37,992 in taxes.

Income Tax	37,992
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +250.00% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+250.00%
50-Day Moving Average	0.00
200-Day Moving Average	0.01
Relative Strength Index (RSI)	46.16
Average Volume (20 Days)	n/a

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, FRA:PBN had revenue of EUR 3.04 million and -6.78 million in losses. Loss per share was -0.00.

Revenue	3.04M
Gross Profit	2.97M
Operating Income	-8.18M
Pretax Income	-6.74M
Net Income	-6.78M
EBITDA	-8.17M
EBIT	-8.18M
Loss Per Share	-0.00

Balance Sheet

The company has 22.70 million in cash and 86,784 in debt, giving a net cash position of 22.61 million.

Cash & Cash Equivalents	22.70M
Total Debt	86,784
Net Cash	22.61M
Net Cash Per Share	n/a
Equity (Book Value)	23.67M
Book Value Per Share	0.00
Working Capital	23.63M

Cash Flow

Operating Cash Flow	-6.39M
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross margin is 97.66%, with operating and profit margins of -269.57% and -223.35%.

Gross Margin	97.66%
Operating Margin	-269.57%
Pretax Margin	-222.10%
Profit Margin	-223.35%
EBITDA Margin	-269.05%
EBIT Margin	-269.57%
FCF Margin	n/a

Dividends & Yields

FRA:PBN does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-75.31%
Shareholder Yield	-75.31%
Earnings Yield	-12.29%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:PBN has an Altman Z-Score of 1.05 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.05
Piotroski F-Score	3